Notes
see Reactions 1469 p3; 803092845
Reference
Therapeutic Goods Administration. Epoetin alfa (Eprex) and increased risk of pure red cell aplasia with subcutaneous administration. Australian Prescriber 5: 201, No. 6, Dec 2014. Available from: URL: http://www.tga.gov.au/publication-issue/medicines-safety-update-volume-5-number-6-december-2014#epoetin
Rights and permissions
About this article
Cite this article
Risk of pure red cell aplasia with SC Eprex: Australian updates. Reactions Weekly 1531, 8 (2014). https://doi.org/10.1007/s40278-014-5641-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-014-5641-5